Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial
- PMID: 22104012
- PMCID: PMC3288479
- DOI: 10.1016/j.parkreldis.2011.11.001
Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial
Abstract
Background: Deep brain stimulation (DBS) of the subthalamic nucleus is an accepted therapy for advanced Parkinson's disease (PD). In animal models, pharmacologic ablation and stimulation of the subthalamic nucleus have resulted in clinical improvement and, in some cases, improved survival of dopaminergic neurons. DBS has not been studied in the early stages of PD, but early application should be explored to evaluate safety, efficacy, and the potential to alter disease progression.
Methods: We are conducting a prospective, randomized, single-blind clinical trial of optimal drug therapy (ODT) compared to medication plus DBS (ODT + DBS) in subjects with Hoehn & Yahr Stage II idiopathic PD who are without motor fluctuations or dementia. We report here subject screening, enrollment, baseline characteristics, and adverse events.
Results: 30 subjects (average age 60 ± 6.9 years, average duration of medicine 2.1 ± 1.3 years, average UPDRS-III scores 14.9 on medication and 27.0 off medication) are enrolled in the ongoing study. Twelve of 15 subjects randomized to DBS experienced perioperative adverse events, the majority of which were related to the procedure or device and resolved without sequelae. Frequently reported adverse events included wound healing problems, headache, edema, and confusion.
Conclusion: This report demonstrates that subjects with early stage PD can be successfully recruited, consented and retained in a long-term clinical trial of DBS. Our ongoing pilot investigation will provide important preliminary safety and tolerability data concerning the application of DBS in early stage PD.
Trial registration: ClinicalTrials.gov NCT00282152.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures
References
-
- Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med. 2004;55:41–60. - PubMed
-
- FDA. [updated 2011 Jul 29; cited 2011 Aug 11];Premarket approval for Medtronic Activa tremor control system. 1997 Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=8621.
-
- Schulz D. Medtronic Activa Parkinson’s control therapy. Rockville, MD: Food and Drug Administration; 2002. [cited 2011 Aug 11]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/p960009S7a.pdf.
-
- Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896–908. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
